Psychological Impact of Atopic Dermatitis in Pediatric Patients
Elizabeth Swanson, MD, and Joshua Zeichner, MD, discuss the psychological factors impacting pediatric patients’ atopic dermatitis.
EP: 1.Characteristics of Type 2 Inflammation and the Impact of Itch
EP: 2.Mechanism of Action for Agents Used to Treat Pediatric Atopic Dermatitis
EP: 3.Psychological Impact of Atopic Dermatitis in Pediatric Patients
EP: 4.Presentation and Diagnosis of Atopic Dermatitis in Pediatrics
EP: 5.Burden of Atopic Dermatitis in Pediatric Patients
EP: 6.Pharmacological Options for the Treatment of Pediatric Atopic Dermatitis
EP: 7.Case 1: 2-Year-Old Male With Atopic Dermatitis
EP: 8.Case 1 Continued: Clinical Impressions
EP: 9.Case 1 Continued: Treatments Beyond Topical Agents and the Use of Dupixent
EP: 10.Case 2: 7-Year-Old Female With Atopic Dermatitis
EP: 11.Case 2 Continued: Impressions and Recommendations
EP: 12.Case 2 Continued: Barriers to Treatment Adherence
EP: 13.Case 2 Continued: Importance of Combination Therapy and Shared Decision Making
EP: 14.Case 2 Continued: Addressing Injectable Medication in Children
EP: 15.Case 3: 12-Year-Old-Female With Atopic Dermatitis
EP: 16.Case 3 Continued: Impressions
EP: 17.Case 3 Continued: How to Have Conversation About Risk of Biologics and Length of Therapy
EP: 18.Take-Home Points
Joshua Zeichner, MD: Let’s change gears and talk about the psychological factors impacting atopic dermatitis. Lisa, I’m going to ask you to take this one.
Elizabeth Swanson, MD: Thank you so much, Josh. Psychological factors play a big role with atopic dermatitis. The biggest one, of course, is stress. When patients are under stress, often their atopic dermatitis gets worse. That can turn into a bit of a vicious cycle because the stress creates a flare of their atopic dermatitis, which stresses them out even more. They go round and round, and their atopic dermatitis flares up. These psychological factors—a lot of which are outside our control, including COVID-19 stressors, school stressors, and family stressors—can drive the disease.
Joshua Zeichner, MD: We see stress as a significant factor in atopic dermatitis and a lot of other conditions in dermatology, whether it’s rosacea, psoriasis, or acne. We can’t underestimate the impact that stress has on the quality of life of the patients who are suffering and their support network: their parents, friends, and teachers. We want to get the disease under control for the whole community.
Transcript Edited for Clarity
Worsening severity of AD in children associated with increased comorbidity onset risk
November 27th 2023Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort, investigators of a Sweden, nationwide, population-based cohort study found.
Lebrikizumab improves AD symptoms for adolescents inadequately controlled with cyclosporine
October 17th 2023Of the patients that responded to lebrikizumab at week 16 in the phase 3 trials ADvocate 1 and ADvocate 2, 84% achieved a clinically meaningful response in at least 1 domain of the disease (mild signs, symptoms, or quality of life impact) at 52 weeks.
Tapinarof cream 1% reduces itch as early as 24 hours after application for pediatric AD
October 13th 2023A rapid reduction in pruritis as early as 24 hours after first application was announced as new positive data from a pair of identical, phase 3 studies of tapinarof cream 1% in children as young as 2 years and adults with atopic dermatitis (AD).
Arcutis submits roflumilast 0.15% sNDA for AD in children 6 years and up
September 21st 2023Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older.
